Gts Securities LLC Biocryst Pharmaceuticals Inc Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$6.41 - $8.69 $10,256 - $13,904	1,600 Added 2.21%	74,000 $562,000
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $101,185 - $166,355	-24,500 Reduced 25.28%	72,400 $447,000
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $23,961 - $37,485	-4,900 Reduced 4.81%	96,900 $492,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $46,812 - $63,637	-9,400 Reduced 8.45%	101,800 $609,000
Q3 2023 Nov 15, 2023	BUY	$6.71 - $7.92 $746,152 - $880,704	111,200 New	111,200 $787,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.